In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 29 of 29

Sort by

Keyword or reference number: chronicRemove Keyword or reference number: chronic filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]	Technology appraisal guidance	7 May 2026
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]	Technology appraisal guidance	TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]	Technology appraisal guidance	TBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]	Technology appraisal guidance	TBC
Bepirovirsen for treating chronic hepatitis B [ID6608]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis	Interventional procedures guidance	TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]	Technology appraisal guidance	TBC
Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449]	Technology appraisal guidance	TBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235	Technology appraisal guidance	11 February 2026
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]	Technology appraisal guidance	TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]	Technology appraisal guidance	TBC
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]	Technology appraisal guidance	29 July 2026
Eneboparatide for treating chronic hypoparathyroidism [ID6532]	Technology appraisal guidance	TBC
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain	Medical technologies guidance	TBC
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]	Technology appraisal guidance	TBC
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237	Technology appraisal guidance	6 August 2026
Middle meningeal artery embolisation for chronic subdural haematomas	Interventional procedures guidance	TBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]	Technology appraisal guidance	23 July 2026
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]	Technology appraisal guidance	29 January 2026
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]	Technology appraisal guidance	TBC
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure	Diagnostics guidance	5 February 2026
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356	Technology appraisal guidance	8 July 2026
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]	Technology appraisal guidance	TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]	Technology appraisal guidance	TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379	Technology appraisal guidance	9 September 2026
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance	TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]	Technology appraisal guidance	TBC

Results per page

10
25
50
All